ERBB2 and breast carcinoma: The expression of immune checkpoint molecules, such as programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), may modulate the immune response in HER2-positive breast cancer [89].